OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Liu on PSMA PET Imaging in Prostate Cancer

April 28th 2023

Jen-Jane Liu, MD, discusses the benefits of using prostate-specific membrane antigen PET imaging in the localized disease setting for patients with prostate cancer, the differences between PSMA PET and conventional imaging, and future considerations for effectively implementing this diagnostic approach in this population.

Dr Crane on PARP Inhibitor Maintenance in Ovarian Cancer

April 28th 2023

Erin K. Crane, MD, MPH, discusses findings from 3 trials demonstrating the benefits of PARP inhibitor maintenance in patients with ovarian cancer.

Dr Bhave on the Impact of New Treatment Strategies on the Landscape of HR+/HER2– Breast Cancer

April 27th 2023

Manali Bhave, MD, discusses the impact of new treatment strategies on the landscape of hormone receptor–positive/HER2-negative breast cancer.

Dr Han on the Use of HIPEC in Ovarian Cancer

April 27th 2023

Ernest S. Han, MD, PhD, discusses the use of hyperthermic intraperitoneal chemotherapy in ovarian cancer.

Dr Noonan on Practice-Changing Trials in HCC

April 27th 2023

Anne M. Noonan, MBBCh, discusses recent practice-changing trials for the treatment of patients with hepatocellular carcinoma.

Dr Jhaveri on RLY-2608 in PIK3CA-Mutant Advanced Breast Cancer

April 27th 2023

Komal Jhaveri, MD, FACP, discusses findings from the dose-escalation portion of the first-in-human phase 1 ReDiscover trial (NCT05216432) of the PI3Kα inhibitor RLY-2608 in patients with PIK3CA-mutant advanced breast cancer.

Dr Suvannasankha on Bispecific Antibodies in Multiple Myeloma

April 27th 2023

Attaya Suvannasankha, MD, discusses future research directions with bispecific antibodies in patients with multiple myeloma and potential methods for mitigating adverse effects in this population.

Dr Taylor on Preliminary Efficacy and Safety Data for IO-108 in Advanced Solid Tumors

April 27th 2023

Matthew H. Taylor, MD, discusses the preliminary data on the use of IO-108 in advanced solid tumors in a phase 1 study.

Dr Han on the Investigation of Gedatolisib in HR+/HER2– Metastatic Breast Cancer

April 26th 2023

Heather Han, MD, discusses prior research with gedatolisib that provided the rationale for the phase 3 VIKTORIA-1 trial (NCT05501886) in patients with hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.

Dr Aggarwal on the Activity of BXCL701 Plus Pembrolizumab in SCNC mCRPC

April 26th 2023

Rahul Aggarwal, MD, discusses key findings from a phase 2a trial evaluating the combination of BXCL701 and pembrolizumab in patients with metastatic castration-resistant prostate cancer with the small cell neuroendocrine cancer phenotype.

Dr Shusterman on a DNA Methylome Enrichment Platform for Early Detection of Solid Tumors

April 26th 2023

Michael Shusterman, MD, discusses findings from a retrospective study to determine the feasibility of a novel genome-wide methylome enrichment platform for the early detection of multiple solid tumors.

Nerlakanti on the Role of HDAC Inhibitors in Osteosarcoma

April 26th 2023

Niveditha Nerlakanti, discusses the investigation of HDAC inhibitors in osteosarcoma.

Dr Tauro on the Role of ULK3 in Multiple Myeloma

April 26th 2023

Marilena Tauro, PhD, discusses the role for ULK3 in regulating autophagy in multiple myeloma.

Dr Stewart on the Multiomic Landscape of Squamous Cell Lung Cancer

April 26th 2023

Paul Stewart, PhD, discusses the multiomic landscape of squamous cell lung cancer.

Dr Wu on the Role of METTL3-Mediated m6A Modification in CLL Progression

April 26th 2023

Yiming Wu, PhD, discusses a study identifying METTL3-mediated N6-methyladenosine modification as a key translational regulator of splicing factors, and how this mechanism contributes to the progression of chronic lymphocytic leukemia.

Nasr on the Need for Preclinical Models of Prostate Cancer Dormancy

April 26th 2023

Mostafa Nasr, PhD candidate, discusses the development of novel preclinical models of prostate cancer dormancy, and the significance of these outcomes may have on future research in metastatic prostate cancer.

Dr Hathaway on the Investigation of Distress on the TME in Ovarian Cancer

April 25th 2023

Cassandra A. Hathaway, MD, discusses the rationale for investigating the association between distress, such as depression, and the tumor immune microenvironment in patients with ovarian cancer.

Dr Bindra on the Role of MGMT Loss on Resistance Mechanisms in Cancer

April 25th 2023

Ranjit S. Bindra, MD, PhD, discusses a new class of DNA modifiers which selectively target tumor DNA with the goal of overcoming resistance mechanisms across multiple types of cancer.

Dr Simeone on the EVEREST-1 Trial Evaluating A2B530 in Solid Tumors

April 25th 2023

Diane M. Simeone, MD, discusses the phase 1/2 EVEREST-1 trial evaluating the autologous CAR T-cell therapy A2B530 in patients with solid tumors.

Dr. McGuinness on Mitigating GI Toxicities With PI3K Inhibitors in PI3K-Mutated Breast Cancer

April 25th 2023

Julia E. McGuinness, MD, discusses combating gastrointestinal toxicities in PI3K-mutated breast cancer.